Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine

Br J Clin Pharmacol. 1982 Feb;13(2):177-85. doi: 10.1111/j.1365-2125.1982.tb01353.x.

Abstract

1 High pressure liquid chromatographic assays for the estimation of sulphinpyrazone and its sulphide, sulphone and p-hydroxy metabolites in plasma and urine are described. 2 Five normal volunteers received 200 mg and 400 mg sulphinpyrazone orally. Sulphinpyrazone was rapidly absorbed and eliminated with a half-life of approximately 4 h irrespective of dose. Peak plasma concentrations and area under the plasma concentration-time curves (AUC) were consistent with linear pharmacokinetic behaviour. 3 Plasma concentrations of the sulphone were low and peaked before those of the sulphide; its mean half-life was 3.1 h. The sulphide, which may be the sulphinpyrazone metabolite with activity on platelets, was eliminated with a mean half-life of 13.4 h. The AUC increases with dose of both metabolites suggested non-linearity. 4 Approximately 45-50% of the administered dose was eliminated in the urine as unchanged drug or as sulphone or p-hydroxy-sulphinpyrazone. The sulphide metabolite was not detected in the urine. The renal clearance of sulphinpyrazone was approximately 18 ml min-1 and that for the sulphone was similar. Sigma minus plots of the urinary excretion yielded half-lives of 3.5 h for the sulphone and 1 h for p-hydroxy-sulphinpyrazone.

MeSH terms

  • Adult
  • Biotransformation
  • Blood Proteins / metabolism
  • Female
  • Half-Life
  • Humans
  • Hydroxylation
  • Kinetics
  • Male
  • Sulfides / metabolism
  • Sulfinpyrazone / blood
  • Sulfinpyrazone / metabolism*
  • Sulfinpyrazone / urine
  • Sulfones / metabolism

Substances

  • Blood Proteins
  • Sulfides
  • Sulfones
  • Sulfinpyrazone